BioStaRT - Biopharmaceutical Stability at Room Temperature
BioStaRT aims to produce lyophilized protein formulations that are stable at room temperature and reconstitute without compromising product quality, particularly aggregation. This stability at room temperature will extend shelf life and reduce the cold chain costs of refrigerated transportation and storage. Current methods for developing protein formulations for subsequent lyophilization are largely empirical, with little understanding of the mechanistic relationships between protein characteristics and formulation impacts, especially electrostatic parameters that influence protein structure and aggregation state during freeze-thawing and freeze-drying. The inventive step in the BioStaRT program is the development and implementation of advanced measurement technologies that integrate microscale down strategies for formulation screening (based on fluorescence, midIR, and NIR microwell analysis) with new methods (LyoDEA) for developing process understanding to increase the success rate for developing room temperature stable biopharmaceuticals.
Feedback Overview:
BioStaRT has a highly innovative approach that addresses a significant pain point in biopharmaceutical logistics by stabilizing proteins at room temperature. To successfully reach product-market fit and increase business value, it is essential to validate the technology through rigorous testing and secure partnerships with major pharmaceutical companies for early adoption. Additionally, focusing on regulatory approvals and scalability will be crucial for market entry and growth.
Market Competitors:
Market Competitor
Market Competitor
Market Competitor
Market Competitor
Market Competitor
Market Competitor
CTO
Expert in biopharmaceutical development and advanced measurement technologies.
What are the main technical challenges in developing room temperature stable biopharmaceuticals?
The main technical challenges include understanding the mechanistic relationships between protein characteristics and formulation impacts, especially electrostatic parameters that influence protein structure and aggregation state during freeze-thawing and freeze-drying.
How can advanced measurement technologies improve the success rate of developing stable formulations?
Advanced measurement technologies can provide more precise and detailed data on protein behavior and formulation impacts, allowing for better optimization and screening of formulations, ultimately improving the success rate.
What are the key factors to consider when scaling up the production of these formulations?
Key factors include maintaining consistency in formulation and process conditions, ensuring regulatory compliance, and optimizing manufacturing processes to handle larger volumes while preserving product quality.